Cheryl Beise
The federal district court in Wilmington, Delaware, did not abuse its discretion in finding that Bayer CropScience’s infringement suit against agrochemical rival Dow AgroSciences over soybean gene technology qualified as an “exceptional case” warranting an award of attorney fees under Section 285 of the Patent Act, the U.S. Court of Appeals for the Federal Circuit has held. Dow’s commercial exploitation of the patents was authorized under the terms of a license between Bayer and a third-party. The district court properly examined the totality of circumstances in finding that Bayer’s litigation conduct and its weak legal positions made the case exceptional (Bayer CropScience AG v. Dow AgroSciences LLC, March 17, 2017, Stoll, K.).
A full summary of this case has been published on Kluwer IP Law
More from our authors:
|
Patent Protection for Second Medical Uses by Jochen Bühling (ed.) € 160 |
|
Competing for the Internet: ICANN Gate – An Analysis and Plea for Judicial Review Through Arbitration by Flip Petillion & Jan Janssen € 205 |
The post USA: Bayer CropScience AG v. Dow AgroSciences LLC, United States Court of Appeals, Federal Circuit, No. 2015-1854, 17 March 2017 appeared first on Kluwer Patent Blog.